Our Leadership

Modus Therapeutics has a Board of Directors and Leadership Team with extensive experience of drug development, partnering and business in life science. This in combination with skilled external expertise, as consultants or advisors, creates a strong team with experience in taking pharmaceutical products to the market.

Board of Directors Leadership Team

Board of Directors

Viktor Drvota M.D, Ph.D
Viktor Drvota M.D, Ph.D
Board Member

Viktor Drvota is Deputy CEO and CIO at Karolinska Development. He has more than 13 years of Venture Capital experience with several investments, significant fundraisings, IPOs and exits.

Mats Wahlgren
Mats Wahlgren
Board Member

Professor Mats Wahlgren investigates the molecular pathogenesis of parasitic diseases. Previous positions include directorship of MTC (KI), the Multilateral Initiative on Malaria and the Infection and Vaccinology Programme (SSF).

Tomas Odergren M.D, Ph.D
Tomas Odergren M.D, Ph.D
Board Member

Dr. Tomas Odergren is an M.D and a Ph.D with a specialist interest in neurology. Dr. Odergren currently holds the position as Chief Expert at H Lundbeck A/S in Denmark.

Torsten Goesch M.D Ph.D
Torsten Goesch M.D Ph.D
Board Member

Dr. Torsten Goesch has been the director of Rosetta Capital secondary life science investor since 2002, where he is responsible for the management of several Rosetta Capital investments.

Björn Sjöstrand
Björn Sjöstrand
Chairman

Bjorn Sjöstrand has extensive experience gained from the vaccines industry in several international executive positions.

Leadership Team

Ellen K. Donnelly, Ph.D
Ellen K. Donnelly, Ph.D
Chief Executive Officer

Ellen K. Donnelly, Ph.D., joined Modus Therapeutics April 2017 from Pfizer, Inc., where she held various leadership positions in Clinical Operations; Project and Portfolio Management; and Research.

Lena Jendeberg Ph.D
Lena Jendeberg Ph.D
Vice President, Development

Joining Modus Therapeutics in 2016, Lena Jendeberg has more than 20 years of experience in research and drug development in biotech and pharma.

Professor Thomas Knittel
Professor Thomas Knittel
Chief Medical Officer

Prof. Knittel has over 10 years of clinical experience in Internal Medicine and more than 15 year's experience in R&D, medical affairs and marketing management in the pharmaceutical/ biotech industry.

Anna Leitgeb Ph.D
Anna Leitgeb Ph.D
Project Leader

Employed in 2005, Anna Leitgeb is one of the inventors of sevuparin and its use in treating VOC in sickle-cell disease and in malaria.